Get access

Stromal-derived factor-1 delivered via hydrogel drug-delivery vehicle accelerates wound healing in vivo

Authors

  • Peter W. Henderson MD, MBA,

    1. Laboratory for Bioregenerative Medicine and Surgery, Division of Plastic and Reconstructive Surgery, Weill Cornell Medical College, New York, New York
    Search for more papers by this author
  • Sunil P. Singh MD,

    1. Laboratory for Bioregenerative Medicine and Surgery, Division of Plastic and Reconstructive Surgery, Weill Cornell Medical College, New York, New York
    Search for more papers by this author
  • David D. Krijgh MSc,

    1. Laboratory for Bioregenerative Medicine and Surgery, Division of Plastic and Reconstructive Surgery, Weill Cornell Medical College, New York, New York
    Search for more papers by this author
  • Masaya Yamamoto PhD,

    1. Department of Genetic Medicine, Howard Hughes Medical Institute, Weill Cornell Medical College, New York, New York
    Search for more papers by this author
  • Daniel C. Rafii BA,

    1. Department of Genetic Medicine, Howard Hughes Medical Institute, Weill Cornell Medical College, New York, New York
    Search for more papers by this author
  • Josephine J. Sung BS,

    1. Laboratory for Bioregenerative Medicine and Surgery, Division of Plastic and Reconstructive Surgery, Weill Cornell Medical College, New York, New York
    Search for more papers by this author
  • Shahin Rafii MD,

    1. Department of Genetic Medicine, Howard Hughes Medical Institute, Weill Cornell Medical College, New York, New York
    Search for more papers by this author
  • Sina Y. Rabbany PhD,

    1. Department of Genetic Medicine, Howard Hughes Medical Institute, Weill Cornell Medical College, New York, New York
    2. Bioengineering Program, Hofstra University, Hempstead, New York
    Search for more papers by this author
  • Jason A. Spector MD

    1. Laboratory for Bioregenerative Medicine and Surgery, Division of Plastic and Reconstructive Surgery, Weill Cornell Medical College, New York, New York
    Search for more papers by this author

  • Presented in part at the 19th Wound Healing Society Annual Meeting in Dallas, Texas, April 26, 2009.

Reprint requests:
Jason A. Spector, MD, 525 East 68th Street, Payson 709-A, New York, NY 10065, USA.
Tel: +1 212-746-4532;
Fax: +1 212-746-8952;
Email: jas2037@med.cornell.edu

ABSTRACT

Topical treatment of superficial wounds has many advantages including decreased cost and increased ease of application compared with systemic treatments. Many of the advantages, however, are lost when it is necessary for repeated doses of topical medications to be given over an extended period of time. Therefore, a drug-delivery vehicle that delivers biologically appropriate doses in a sustained fashion would prove valuable. In this study, an alginate hydrogel scaffold impregnated with the angiogenic chemokine stromal-derived factor-1 was used to provide targeted, though short-term, delivery directly into the wound bed. Wounds were created on the dorsum of mice, and either a stromal-derived factor-1-impregnated or a saline-impregnated scaffold was applied. Wounds were explanted after 1, 3, 7 days, wound area was measured, and histology and immunohistochemistry for endothelial markers were performed. The remaining wound area in stromal-derived factor-1-treated wounds vs. controls was not significant 1 day after wounding (96.7±0.1 vs. 97.5±1.1%, p=0.317), but was significant after 3 days postwounding (46.7±0.1 vs. 82.3±2.4%, p=0.046) and 7 days postwounding (2.3±1.3 vs. 32.0±4.0%, p=0.049). Immunohistochemistry revealed a greater degree of endothelial cell invasion into the wound bed infiltration compared with controls. The results of this study suggest significant clinical promise for our hydrogel-delivery vehicle in the treatment of wounds.

Ancillary